Catalent today announced that it is investing $130 million to add five additional Phase 3 through commercial-scale manufacturing suites to its gene therapy campus in Harmans, Maryland.
Exelixis, Inc. and Catalent today announced a partnership under which Catalent will develop multiple ADCs for Exelixis using Catalent’s proprietary SMARTag® technology.
Catalent today announced that it is investing $50 million to install an additional high-speed vial filling line at its Bloomington, Indiana, facility.
Catalent today announced that two Catalent Biologics experts will present at the upcoming 16th Annual PEGS Boston Virtual Conference & Expo, taking place between Aug. 31 – September 4, 2020.
Catalent Cell & Gene Therapy will provide drug substance manufacturing for the University of Oxford’s adenovirus vector-based vaccine at Catalent’s Harmans, Maryland gene therapy manufacturing facility.
Catalent today announced it will present at the upcoming World Orphan Drug Congress Annual Meeting, which will take place virtually on Aug. 24 – 26, 2020.